Geron Corporation (GERN) on Monday provided financial guidance for 2026, expecting net product revenue for Rytelo in the range of $220 million to $240 million.
The company said its 2026 outlook reflects expected top-line growth alongside a reduction in operating spend year over year.
Total operating expenses are expected in the range of $230 million to $240 million in 2026.
Rytelo is approved in the U.S. for the treatment of lower-risk myelodysplastic syndrome (LR-MDS) with transfusion-dependent anemia. It is also approved in the European Union as a monotherapy for adult patients with transfusion-dependent anemia due to very low, low, or intermediate-risk myelodysplastic syndromes.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.